Broadly Neutralizing Antibodies: Magic Bullets against HIV?

Boris Julg, Galit Alter

Open access · bronzeAbstract readComment

In one paragraph

Article in Immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

0.4field-weighted citation impact, top 34% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection.Viruses · 2024
Review
Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Frontiers in immunology · 2017
Review

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Boris JulgRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.

Galit AlterRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: galter@partners.org.

Ragon Institute of MGH, MIT and Harvard · US

Funding

Vaccine induced T-cell protection against SIV infectionK08AI106408 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI JUELG, BORIS DOMINIK · 2013 to 2017

$938k

NIAID NIH HHS K08 AI106408

6 · The paper itself

Abstract

Broadly neutralizing antibodies (bNAbs) offer new avenues for HIV prevention and cure strategies. Three recent papers, published in Science and Nature, highlight the broad applicability of bNAbs in HIV cure and prevention and in boosting immunity against HIV.

Indexed as

Antibodies, NeutralizingHIV-1HIV AntibodiesHIV InfectionsHumansAntibodies, NeutralizingHIV Antibodies

Identifiers

PMID27332729

DOI10.1016/j.immuni.2016.06.012

OpenAlexW2472240741

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.